ROCKVILLE, MARYLAND, March 4, 2013 – BioHealth Innovation, Inc. (BHI), a regional private-public partnership focusing on commercializing market-relevant biohealth innovations and increasing access to early-stage funding in Central Maryland, today announced that BioHealth Innovation, Inc. President & CEO Richard Bendis is scheduled to present at the upcoming SXSW 2013 conference and the 2013 BIO International Convention this Spring. Mr. Bendis is also serving on the Program Committee for AdvaMed 2013: The MedTech Conference, which will be held in Washington, DC, in September.

Specific information for each event is as follows:

• 2013 South By Southwest "SXSW" Conference, March 8-12, 2013, Austin Convention Center, Austin, Texas. Mr. Bendis is participating in a panel on Saturday, March 9, entitled, "Entrepreneurs-in-Residence: Not Just for VCs!" Venture capital firms have utilized the services of 'Entrepreneurs-in-Residence' (EIRs), seasoned innovators with functional expertise, to help spur entrepreneurship and fill gaps in expertise. This panel will look at the value of combining the 'innovation mojo' of EIRs with some of the government's brightest 'intrapreneurs' to solve the nation's most pressing challenges. Joining Mr. Bendis on the panel will be Arnaub Chatterjee (Associate Director of Health Information Partnerships, Merck - Office of the Chief Medical Information and Innovation Officer), John Paul Farmer (Senior Advisor to the U.S. CTO) and Zachery Jiwa, Health IT Advisor; Innovation Fellow, U.S. Department of Health and Human Services; Advisor, HIMSS State Advisory Roundtable.
  
  
• 2013 BIO International Convention, April 22-23, 2013, McCormick Place, Chicago, Illinois. Mr. Bendis is scheduled to be part of The Translational Research Forum on April 22, 2013, beginning at 1:30 p.m., and a panel discussion focused on effective strategies in developing accelerator models beginning at 4:35 p.m.
  
  
• AdvaMed 2013: The MedTech Conference, September 23-25, 2013, Walter E. Washington Convention Center, Washington, DC. Mr. Bendis is reviewing panel submissions in the eHealth IT Track.

ROCKVILLE, MARYLAND, February 11, 2013 – BioHealth Innovation, Inc. (BHI), a regional private-public partnership focusing on commercializing market-relevant biohealth innovations and increasing access to early-stage funding in Central Maryland, announced today the appointment of GenVec, Inc. President and Chief Executive Officer Cynthia L. Collins to its Board of Directors. BHI also announced that BHI Founding Board Member Jerry Parrott, formerly with Human Genome Sciences, has stepped down from his board seat but will continue to remain active on BHI's Commercial Relevance Advisory Board.

ROCKVILLE, MARYLAND, February 27, 2013 – BioHealth Innovation, Inc. (BHI), a regional private-public partnership focusing on commercializing market-relevant biohealth innovations and increasing access to early-stage funding in Central Maryland, announced today the formation of its Commercial Relevance Advisory Board (CRAB). Members of the CRAB represent diverse business and academic organizations from throughout the region, such as venture capital firm New Enterprise Associates, Ernst & Young, the Howard Hughes Medical Institute, the University of Maryland (UMD), Johns Hopkins University, and leading biotechnology companies.

BHI and Ahead are collaborating to accelerate commercialization of Symcat, Ahead Research’s patient/healthcare provider matchmaking app

ROCKVILLE, MARYLAND, Dec. 19, 2012 - BioHealth Innovation, Inc. (BHI) announced today that its newest client, Ahead Research, Inc. (Ahead), received the first Cigna Innovation Health Challenge award at the 2012 mHealth summit. BHI and Ahead recently signed a Memorandum of Understanding (MOU) to jointly accelerate the commercialization of Symcat, Ahead’s web and mobile application whose module was the basis for the Cigna award.

“Ahead Research – with its Symcat app – is the type of entrepreneurial start-up company that BioHealth Innovation seeks to foster as part of its mission to drive the commercialization of market-relevant biohealth innovations,” said BioHealth Innovation’s President & CEO Richard Bendis.

ROCKVILLE, MARYLAND, Dec. 19, 2012 - BioHealth Innovation, Inc. (BHI), a regional private-public partnership focusing on commercializing market-relevant biohealth innovations and increasing access to early-stage funding in Central Maryland, announced today the appointment of Emergent BioSolutions Inc. President and CEO Daniel J. Abdun-Nabi and SR One President Jens Eckstein, Ph.D., to the BHI Board of Directors.

"It is an honor to welcome two additional life science industry leaders to the BHI Board of Directors," said BioHealth Innovation's President & CEO Richard Bendis. "Dan brings a unique perspective from his role at the helm of one of the leading specialty pharmaceutical companies while Jens will provide important insight as the head of the corporate venture capital arm of GlaxoSmithKline (GSK). I'm also incredibly pleased that GSK, after having acquired Human Genome Sciences (one of the original investors in BHI), will continue to support BHI and has expressed an understanding of the importance of the mission of our organization."